Myotonic dystrophy type 1: treatments
Evidence-based neurology checklist on myotonic dystrophy type 1: treatments: Myotonia Mexiletene Phenytoin Procainamide Tricyclics Benzodiazepine Heated gloves Fatigue and daytime sleepiness Arrhythmias Cardiomyopathy Ophthalmic disorders Gastrointestinal disorders Respiratory dysfunction…
Myotonia
- Mexiletene
- Phenytoin
- Procainamide
- Tricyclics
- Benzodiazepine
- Heated gloves
Fatigue and daytime sleepiness
Arrhythmias
Cardiomyopathy
Ophthalmic disorders
Gastrointestinal disorders
Respiratory dysfunction
Vaccinations
Investigational treatments
References
- Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. JNNP 2010; 81:358-367.
- Longman C. Myotonic dystrophy. J R Coll Physicians Edin 2006; 36:51-55.
- Ashizawa T, Gagnon C, Groh WJ, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract 2018; 8:507-520.
- Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74:1441-1448.
- Heatwole C, Luebbe E, Rosero S, et al. Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. Neurology 2021; 96:e228-e240.
- And 7 more. Subscribe to see the full list
Related checklists
- Myotonic dystrophy type 1: neurological features
- Myotonic dystrophy type 1: major systemic features
- Myotonic dystrophy type 1: other systemic features
- Myotonic dystrophy type 1 and cancer
- Myotonic dystrophy type 1: investigations
- Myotonic dystrophy type 1: surveillance
- Myotonic dystrophy type 1: anaesthetic management
- Myotonic dystrophy type 1: outcome